cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine
Biologicalexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2015 (NCT02157051)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cd105/yb-1/sox2/cdh3/mdm2-polyepitope plasmid dna vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07078604 | Phase 2 | Dec 1, 2025 | Kuni Foundation, University of Washington |
| NCT07112053 | Phase 2 | Nov 24, 2025 | University of Washington |
| NCT05455658 | Phase 2 | Jan 5, 2023 | National Cancer Institute (NCI), University of Washington, University of Wisconsin |
| NCT05242965 | Phase 2 | Dec 30, 2022 | Department of Defense, University of Washington |
| NCT02157051 | Phase 1 | Jun 1, 2015 | Department of Defense, National Cancer Institute (NCI), University of Washington |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Washington | Academic/Hospital | 5 | 5 | 2 | 2015 |
| Department of Defense | Government | 2 | 0 | 2 | 2015 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2015 |
| Kuni Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1